BioSpace News Archive

Eikonizo Therapeutics, Inc., a biotechnology company developing novel, first-in-class brain-penetrant HDAC6 inhibitors to slow or stop progression of neurodegenerative disorders, has published results from the First-in-Human Study of [18F]EKZ-001 in healthy volunteers in the European Journal of Nuclear Medicine and Molecular Imaging.

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented company focused on manufacturing and marketing aerosol delivery systems based on pressurized Metered Dose Inhaler (MDI) technology, announced today that it has delivered an initial 2,000 units under its previously announced 100,000 unit order. Rapid Therapeutic Science Laboratories, Inc. Chairman and CEO, Donal R. Schmidt, Jr. stated, “RTSL is moving forw

Largest study of a nationally representative American population demonstrates cotesting outperforms HPV or Pap testing alone in detecting cancer and precancer in women 30 years and older

RGX-111 and RGX-121 continue to be well-tolerated in patients with MPS I and MPS II following one-time intracisternal administration

Concert Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543, for the treatment of adult patients with moderate-to-severe alopecia areata.

Foghorn® Therapeutics Inc., a company advancing an unprecedented class of therapeutics targeting the chromatin regulatory system in oncology, announced that it has entered into a strategic collaboration with Merck, known as MSD outside the United States and Canada.

PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that it has successfully completed the three-month product stability testing that is required by the U.S. Food and Drug Administration for its CypCaps™ and CypCaps™ passed all of the FDA-required tests.

The Grant from the Bill & Melinda Gates Foundation Accelerates Company’s Efforts to Enter Clinical Trials by Early 2021

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical programs, highlighted by the restart of patient enrollment in the Company’s pivotal Phase 3 VIITAL™ study of EB-101, its autologous, gene-corrected cell therapy, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Enrollment in the VIITAL™ study at Stanford University Medical Cen

Nephros , Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced preliminary financial results for the quarter ended June 30, 2020. Net revenues for the quarter are expected to be $1.6 million, a decrease of approximately 33% compared